RxDoctor Payments Data

Jessin Helmrick-Blossom, MD

MOHS-Micrographic Surgery · Ocala, FLNPI 1265661680

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,920 of the $9,892 with a category attached, or 80.1%. 35 manufacturers reported payments, led by AbbVie at 31.9% of the total. Reporting peaked in 2024 at $2,515 and has fallen 77.8% since, to $559 in 2025.

$9,892in general payments, 2019–2025

Across 295 payments — averaging $33.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Sun Pharmaceutical Industries Inc.$916
  • Regeneron Healthcare Solutions, Inc.$869
  • Novartis$799
  • Galderma Laboratories, L.p.$599
  • Amgen$410
  • plus $3K from 29 others

What the payments were for

  • Travel & lodging$1,74918%
  • Food & beverage$7,92080%
  • Education$2232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,892 in reported general payments places this provider in the 85th percentile of 141 mohs-micrographic surgery providers in Florida.

See all mohs-micrographic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$449,942
Medicare patients
503
Services billed
2,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol Propionate23$875
Doxycycline Hyclate27$574
Triamcinolone Acetonide28$363
Clindamycin Phosphate11$304
Terbinafine Hcl15$301
Ketoconazole15$143
Mupirocin17$135

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →